Brokerages Set Cencora, Inc. (NYSE:COR) Target Price at $393.08

Shares of Cencora, Inc. (NYSE:COR) have been given an average recommendation of “Moderate Buy” by the thirteen research firms that are covering the firm, MarketBeat reports. Three investment analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $393.0833.

Several analysts recently issued reports on the stock. Mizuho boosted their price objective on shares of Cencora from $340.00 to $380.00 and gave the company an “outperform” rating in a report on Thursday, November 6th. Barclays assumed coverage on shares of Cencora in a research report on Monday, December 8th. They set an “overweight” rating and a $400.00 price target for the company. Wells Fargo & Company upped their price objective on shares of Cencora from $354.00 to $405.00 and gave the stock an “overweight” rating in a report on Tuesday, November 11th. Robert W. Baird set a $415.00 price objective on shares of Cencora in a research report on Tuesday, January 13th. Finally, JPMorgan Chase & Co. boosted their target price on Cencora from $344.00 to $417.00 and gave the company an “overweight” rating in a research report on Tuesday, November 11th.

Insider Activity at Cencora

In other Cencora news, EVP Silvana Battaglia sold 1,677 shares of Cencora stock in a transaction dated Friday, December 19th. The stock was sold at an average price of $345.00, for a total value of $578,565.00. Following the completion of the transaction, the executive vice president directly owned 18,796 shares of the company’s stock, valued at $6,484,620. The trade was a 8.19% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Robert P. Mauch sold 5,096 shares of the stock in a transaction dated Tuesday, November 18th. The stock was sold at an average price of $366.64, for a total transaction of $1,868,397.44. Following the sale, the chief executive officer directly owned 65,746 shares in the company, valued at $24,105,113.44. This represents a 7.19% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 20,316 shares of company stock worth $7,151,265 in the last three months. 0.38% of the stock is owned by company insiders.

Institutional Trading of Cencora

A number of large investors have recently modified their holdings of the stock. Vanguard Group Inc. grew its stake in Cencora by 4.1% during the 3rd quarter. Vanguard Group Inc. now owns 23,395,547 shares of the company’s stock worth $7,311,810,000 after purchasing an additional 916,506 shares in the last quarter. State Street Corp grew its position in shares of Cencora by 9.3% during the third quarter. State Street Corp now owns 9,190,316 shares of the company’s stock worth $2,872,249,000 after buying an additional 782,911 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of Cencora by 6.3% during the second quarter. Geode Capital Management LLC now owns 4,787,609 shares of the company’s stock worth $1,429,772,000 after buying an additional 284,229 shares during the period. JPMorgan Chase & Co. raised its holdings in Cencora by 21.3% in the third quarter. JPMorgan Chase & Co. now owns 4,677,797 shares of the company’s stock valued at $1,461,965,000 after acquiring an additional 821,098 shares in the last quarter. Finally, Boston Partners lifted its stake in Cencora by 2.0% in the third quarter. Boston Partners now owns 4,509,165 shares of the company’s stock worth $1,409,152,000 after acquiring an additional 89,506 shares during the last quarter. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Cencora Stock Performance

NYSE:COR opened at $350.13 on Friday. The company’s 50-day moving average is $347.96 and its two-hundred day moving average is $323.25. Cencora has a 1-year low of $237.71 and a 1-year high of $377.54. The company has a debt-to-equity ratio of 4.32, a current ratio of 0.90 and a quick ratio of 0.55. The firm has a market capitalization of $67.92 billion, a price-to-earnings ratio of 44.04, a PEG ratio of 1.69 and a beta of 0.66.

Cencora (NYSE:COR) last released its quarterly earnings results on Wednesday, November 5th. The company reported $3.84 EPS for the quarter, beating the consensus estimate of $3.79 by $0.05. The firm had revenue of $83.73 billion for the quarter, compared to analyst estimates of $83.36 billion. Cencora had a net margin of 0.48% and a return on equity of 227.15%. The business’s revenue for the quarter was up 5.9% compared to the same quarter last year. During the same quarter in the previous year, the company earned $3.34 EPS. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. Analysts forecast that Cencora will post 15.37 EPS for the current year.

Cencora Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, December 1st. Investors of record on Friday, November 14th were paid a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a yield of 0.7%. The ex-dividend date of this dividend was Friday, November 14th. This is a positive change from Cencora’s previous quarterly dividend of $0.55. Cencora’s dividend payout ratio is currently 30.19%.

About Cencora

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.